This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
PAHC vs. SYK: Which Stock Is the Better Value Option?
by Zacks Equity Research
PAHC vs. SYK: Which Stock Is the Better Value Option?
Boston Scientific (BSX) EXALT Gets CE Nod, Endoscopy Arm Grows
by Zacks Equity Research
The European market release of Boston Scientific's (BSX) EXALT Model B Single-Use Bronchoscope will mitigate infection risks associated with reusable imaging scopes.
Here's Why You Should Add Phibro (PAHC) to Your Portfolio
by Zacks Equity Research
Investors are optimistic about Phibro (PAHC) on solid third-quarter performance and potential in emerging markets.
PAHC vs. SYK: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
PAHC vs. SYK: Which Stock Is the Better Value Option?
Phibro (PAHC) Q3 Earnings Beat Estimates, Margins Decline
by Zacks Equity Research
Phibro's (PAHC) fiscal third-quarter revenues improved year over year on growth in Performance Products and Mineral Nutrition segments.
Here's Why You Should Add Phibro (PAHC) to Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Phibro (PAHC), owing to its potential in Performance Products and consistent high demand for its nutritional specialty products.
PAHC or SRDX: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
PAHC vs. SRDX: Which Stock Is the Better Value Option?
Why Is Phibro (PAHC) Up 1.1% Since Last Earnings Report?
by Zacks Equity Research
Phibro (PAHC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
PAHC or RMD: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
PAHC vs. RMD: Which Stock Is the Better Value Option?
Phibro (PAHC) Q2 Earnings Surpass Estimates, Margins Up
by Zacks Equity Research
Phibro's (PAHC) second-quarter revenue declined 3.7% year over year to $206.1 million and gross profit improved 33%.
PAHC vs. SRDX: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
PAHC vs. SRDX: Which Stock Is the Better Value Option?
Phirbo (PAHC) Nutritional Specialty Aids Growth, Low ASP Ails
by Zacks Equity Research
Phirbo's (PAHC) net vaccine sales remain robust on higher international demand for poultry vaccines.
Why Is Phibro (PAHC) Up 1.4% Since Last Earnings Report?
by Zacks Equity Research
Phibro (PAHC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Phibro (PAHC) Hurt by Adverse Pricing in Mineral Nutrition Arm
by Zacks Equity Research
Lower sales of Phibro's (PAHC) Performance Products arm's copper-based products raise concerns.
Phibro (PAHC) Q1 Earnings Surpass Estimates, Margins Up
by Zacks Equity Research
Phibro's (PAHC) core Animal Health segment, along with strength in Nutritional Specialties and Vaccines, boosted Q1 performance despite pandemic-led business disruptions.
PAHC vs. RMD: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
PAHC vs. RMD: Which Stock Is the Better Value Option?
Why Is Phibro (PAHC) Down 14.8% Since Last Earnings Report?
by Zacks Equity Research
Phibro (PAHC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Phirbo's Product Mix Aids, Global Animal Health Business Ails
by Zacks Equity Research
Phirbo (PAHC) catered industries face issues like lack of processing availability and sudden drop in demand.
Phibro (PAHC) Q4 Earnings Fall Short of Estimates, Margins Up
by Zacks Equity Research
Phibro's (PAHC) core Animal Health segment was aided by the Osprey Biotechnics acquisition despite a dismal overall performance in Q4 due to pandemic-led business disruptions.
Phibro (PAHC) Q3 Earnings Surpass Estimates, Margin Declines
by Zacks Equity Research
Phibro (PAHC) witnessed revenue uptick in its core Animal Health segment in Q3 despite the coronavirus-led business disruptions in the animal production industry.
Here's Why You Should Add Tandem Diabetes to Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Tandem Diabetes (TNDM) on its strength in the diabetes business and receipt of regulatory approvals.
Walgreens' Retail Pharmacy Grows Amid Coronavirus Crisis
by Zacks Equity Research
Walgreens (WBA) registers growing demand for Retail Pharmacy & Pharmaceutical Wholesale products in Q2.
Abbott Launches Antibody Test to Detect Coronavirus Infection
by Zacks Equity Research
Abbott (ABT) launches a lab-based serology blood test to detect the presence of antibodies post the coronavirus infection.
QIAGEN Launches Assay for Cancer Patients Following FDA's Nod
by Zacks Equity Research
QIAGEN (QGEN) paves the way for metastatic CRC treatment in adults with the launch of an FDA-approved companion diagnostic test kit.
NuVasive (NUVA) Posts Q1 Preliminary Results, Withdraws View
by Zacks Equity Research
A decline in elective surgical procedures due to coronavirus outbreak weighs on NuVasive's (NUVA) preliminary revenue results for first-quarter 2020.